🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 69 of 116

  1. S95012 concentrate solution for infusion 400mg/ 16 ml, Gazyvaro 1,000 mg concentrate for solution for infusion.

    The George Institute

    Soild Tumors

    phase 2 small molecule active

    1 trial

  2. SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immuno-chemotherapy in patients with early triple-negative breast cancer (TNBC). An open-label randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK

    The George Institute

    Early triple-negative breast cancer (TNBC)

    phase 2 other active

    1 trial

  3. SAR439859, Verzenios 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, Verzenios 150 mg film-coated tablets, IBRANCE 75 mg hard capsules, Verzenios 50 mg film-coated tablets, IBRANCE 100 mg hard capsules

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  4. SAR444881

    Regeneron UK Limited

    Solid Tumors

    phase 2 small molecule active

    1 trial

  5. SARS-CoV-2 mRNA Vaccine ARCT-021

    Arcturus Therapeutics Holdings

    Hematopoietic and Lymphatic System Neoplasm

    phase 2 mab active

    1 trial

  6. SCB01A

    Biotech Pharmaceutical Co.,

    Head and Neck Neoplasms

    phase 2 small molecule terminated

    1 trial

  7. SDREGN2810

    Regeneron UK Limited

    Advanced Non-Small Cell Lung Carcinoma

    phase 2 small molecule terminated

    1 trial

  8. SDX-105

    Teva Pharma GmbH

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  9. SELPERCATINIB, SELPERCATINIB

    Wuhan Createrna Science and Technology Co., Ltd

    Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.

    phase 2 small molecule active

    1 trial

  10. SELPERCATINIB, Selpercatinib, Selpercatinib, SELPERCATINIB, Selpercatinib

    Wuhan Createrna Science and Technology Co., Ltd

    Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  11. SELUMETINIB, CASODEX 50 mg compresse rivestite con film, OLAPARIB

    Istituto Gentili S.r.l.

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

  12. SG+I

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    TNBC, Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  13. SHR-1210

    Hospital Authority, Hong Kong

    Renal Cell Carcinoma

    phase 2 mab active

    1 trial

  14. SHR-1210

    The First People's Hospital of Lianyungang

    Resectable Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  15. SHR-1701

    The First People's Hospital of Lianyungang

    Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  16. SHR-1701 Combined With Fluazopalil

    Hunan Province Tumor Hospital

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. SHR2554/AZA + Overlapped TBF

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 other active

    1 trial

  18. SI-B001

    Sichuan Baili Pharmaceutical Co.,

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. SILIMARIN 200 mg compresse rivestite, Kisqali 200 mg film-coated tablets

    Fondazione Telethon ETS

    hormone receptor positive, HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  20. SILTUXIMAB , PREDNISOLONE , CYCLOPHOSPHAMIDE , CARBOPLATIN , PARACETAMOL , ETOPOSIDE , VINCRISTINE , LENALIDOMIDE , DIPHENHYDRAMINE , GEMCITABINE , PREDNISONE , OXALIPLATIN , TOCILIZUMAB , Epcoritamab, Epcoritamab, DEXAMETHASONE , DOXORUBICIN , CYTARABINE , RITUXIMAB , IFOSFAMIDE , ANAKINRA , BENDAMUSTINE

    Genmab A/S

    Lymphoma of B-cell origin

    phase 2 small molecule active

    1 trial

  21. SILTUXIMAB, Tarlatamab, Tarlatamab

    Amgen

    Small Cell Lung Cancer (SCLC)

    phase 2 small molecule active

    1 trial

  22. SIRT Yttrium-90

    Chinese University of Hong Kong

    Cholangio Carcinoma

    phase 2 small molecule completed

    1 trial

  23. SKB103 for injection monotherapy

    Sichuan Provincial People's Hospital

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  24. SNDX-5613

    Syndax Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  25. SNS-101 (anti-VISTA)

    Regeneron UK Limited

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  26. SNS-301

    Sensei Biotherapeutics

    Squamous Cell Carcinoma of the Head and Neck

    phase 2 small molecule terminated

    1 trial

  27. SODIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE MONOHYDRATE

    The George Institute

    Colon cancer

    phase 2 small molecule active

    1 trial

  28. SOTORASIB

    Amgen

    KRAS p.G12C Mutant Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  29. SOTORASIB

    Amgen

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  30. SOX Chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  31. SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

    Lacuna Pharma Pty Ltd

    Hypercortisolism related to benign adrenal tumour

    phase 2 other active

    1 trial

  32. SPRYCEL 70 mg film-coated tablets, Venetoclax, SPRYCEL 100 mg film-coated tablets, Venetoclax, SPRYCEL 20 mg film-coated tablets, Venetoclax, SPRYCEL 50 mg film-coated tablets, Venetoclax, Venetoclax, Venetoclax, SPRYCEL 10 mg/mL powder for oral suspension

    AXIM BIOTECHNOLOGIES, INC.

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  33. SRF388

    Coherus Oncology

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  34. SRF617

    Arcus Biosciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  35. SSGJ-706+XELOX

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gastric/Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  36. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

    phase 2 small molecule active

    1 trial

  37. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  38. STC-15 in combination with toripalimab

    Coherus Oncology

    Solid Tumor

    phase 2 other active

    1 trial

  39. STRO-002

    SUTRO BIOPHARMA, INC.

    Neoplasm Malignant

    phase 2 mab completed

    1 trial

  40. SV-BR-1-GM

    BriaCell Therapeutics

    Breastcancer

    phase 2 mab completed

    1 trial

  41. SX-682

    United Therapeutics Europe Ltd

    Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  42. SY-1425, AZACITIDINE

    Lacuna Pharma Pty Ltd

    Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)

    phase 2 small molecule active

    1 trial

  43. Sacituzumab Tirumotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Extensive-Stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  44. Sacituzumab Tirumotecan and Limertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    EGFR-mutant Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  45. Sacituzumab Tirumotecan in combination with tislelizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  46. Sacituzumab tirumotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    TNBC - Triple-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  47. Safety and efficacy of IMM-101 combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer (MEPANC-1)

    Disc Medicine

    Limited metastatic pancreatic cancer

    phase 2 other active

    1 trial

  48. Sandwich stratergy

    The First People's Hospital of Lianyungang

    Acute Lymphobkastic Leukemia

    phase 2 other active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.